Cytochrome Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics that restore mitochondrial Complex I function in Parkinson's disease. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cytochrome targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD["@cytocephalus"].
...
Cytochrome Therapeutics
Overview
Mermaid diagram (expand to render)
Cytochrome Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics that restore mitochondrial Complex I function in Parkinson's disease. Founded in 2019 and headquartered in Cambridge, Massachusetts, Cytochrome targets the fundamental bioenergetic defect that underlies dopaminergic neuron degeneration in PD["@cytocephalus"].
The company's lead program, CT-101, is a first-in-class small molecule designed to repair and restore Complex I activity, addressing the root cause of mitochondrial dysfunction in Parkinson's disease rather than just treating symptoms.
Scientific Rationale
Mitochondrial Complex I Deficiency in PD
Mitochondrial Complex I (NADH:ubiquinone oxidoreductase) deficiency is one of the most consistent biochemical findings in Parkinson's disease:
Post-mortem studies: Reduced Complex I activity has been documented in substantia nigra of PD patients[@mitochondrial]
Genetic links: PINK1 and Parkin mutations cause familial PD through mitophagy pathway disruption
Environmental factors: MPTP, rotenone, and other Complex I inhibitors cause parkinsonian syndromes
Bioenergetic crisis: Loss of Complex I leads to ATP depletion and increased ROS production
CT-101 Mechanism of Action
CT-101 is a small molecule designed to:
Rebuild Complex I assembly: Promotes proper assembly of the 45-subunit Complex I
Restore electron transfer: Improves NADH oxidation and electron flow
Reduce ROS generation: Decreases reactive oxygen species from dysfunctional mitochondria
Protect dopaminergic neurons: Preserves neurons in the substantia nigra pars compacta
Pipeline Overview
| Drug | Mechanism | Indication | Phase | Status | |------|-----------|------------|-------|--------| | CT-101 | Complex I restorer | Parkinson's Disease | Phase 1b | Active | | CT-201 | Complex I restorer | Parkinson's Disease | Preclinical | IND-enabling | | CT-301 | Neuroprotective | PD-related dementia | Discovery | Research |
Clinical Development
CT-101 Phase 1 Program
Phase 1a (2024): Single ascending dose study in healthy volunteers demonstrated safety and tolerability at doses up to 200mg with no serious adverse events[@cytocephalusa].
Phase 1b (2025): Multiple ascending dose study in early PD patients (Hoehn & Yahr stages 1-2) is underway, with primary endpoints including:
Safety and tolerability
Pharmacokinetic parameters
Biomarkers of mitochondrial function (ATP, lactate, PINK1 levels)
Motor function assessments (MDS-UPDRS)
Clinical Trial Design
The Phase 1b trial employs a randomized, double-blind, placebo-controlled design:
PINK1 knockout model: Improved mitochondrial function and behavior
Aging mouse model: Restored age-related Complex I decline
Mechanism Validation
Increased Complex I activity in substantia nigra
Reduced oxidative stress markers (8-OHdG, 4-HNE)
Improved ATP production in brain tissue
Preserved tyrosine hydroxylase-positive neurons
Corporate Information
| Attribute | Details | |-----------|---------| | Headquarters | Cambridge, Massachusetts, USA | | Founded | 2019 | | CEO | Dr. Sarah Chen | | Funding | Series B ($45M, 2023) | | Investors | Atlas Venture, Third Kind Ventures, Mission Bay Capital |
Scientific Advisory Board
Dr. Birgit K. H. Winkler — Mitochondrial biology, University of Cambridge
Dr. James T. B. Green — Parkinson's disease research, Harvard Medical School